Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Zambon SpA clinical trials
The registry lists 24 studies whose lead sponsor is Zambon SpA or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 15, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Zambon SpA.
- Zambon SpA23 studiesSame company
Something wrong?
- Zambon SAU1 study →Regional office
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 24 of 24.
- Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.TerminatedNCT03460704Phase 3
- Study to Compare the Effects of Z7200 And Symbicort® Turbohaler on Respiratory Imaging Parameters in Asthmatic PatientsCompletedNCT02227394Phase 2
- A Retrospective Chart Review Study of Patients With CLAD-BOS Post Lung TransplantationCompletedNCT06503770
- Extension Trial on Efficacy / Safety of L-CsA + SoC in Treating BOS in Post Single or Double Lung Transplant (BOSTON-3)TerminatedNCT04039347Phase 3
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)CompletedNCT03656926Phase 3
- Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-1)CompletedNCT03657342Phase 3
- A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus SecretionsCompletedNCT03843541Phase 3
- An Observational Study on Safinamide, Rasagiline and Other Standard of Care in PDCompletedNCT03994328
- A Study to Evaluate the Efficacy and Safety of Safinamide, as add-on Therapy, in Idiopathic Chinese Parkinson's Disease (PD) Patients With Motor Fluctuations Treated With Stable Doses of LevodopaCompletedNCT03881371Phase 3
- Efficacy and Safety of Inhaled CMS in Bronchiectasis Subjects With Chronic P. Aeruginosa Infection. (PROMIS-I)CompletedNCT03093974Phase 3
- A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4)TerminatedNCT04107675Phase 2
- Effect of Safinamide on Parkinson's Disease Related Chronic PainCompletedNCT03841604Phase 4
- A Single and Multiple Dose Study to Assess How the Drug Enters, Moves Through and Exits the Body, Safety and Tolerability of Safinamide in Healthy Adult Chinese VolunteersCompletedNCT03887221Phase 1
- Clinical Study to Evaluate Z7200 Pharmacokinetics ProfileCompletedNCT02631941Phase 1
- A Clinical Study to Evaluate Z7200 (Budesonide/Formoterol) Pharmacokinetics Profile in Healthy VolunteersCompletedNCT02237508Phase 1
- Durolane SJ for Treatment of RhizarthrosisCompletedNCT02676284Not applicable
Sponsor listed in the registry: Zambon SAU
- Phase 1 Three Part SAD, MAD & Cross-Over Study of ZP-059 in Healthy and Asthmatic SubjectsCompletedNCT04229303Phase 1
- Bioequivalence Study of Two Different Formulations of N-acetyl-cysteine (NAC)CompletedNCT02265224Phase 1
- Safinamide for Multiple System Atrophy (MSA)CompletedNCT03753763Phase 2
- A Study to Evaluate Pharmacokinetics, Safety and Tolerability of Single and Multiple Intravenous Doses of N-acetylcysteine (NAC) in Chinese Healthy VolunteersCompletedNCT03881163Phase 1
- Safinamide for Levodopa-induced Dyskinesia (PD-LID)WithdrawnNCT03987750Phase 3
- Efficacy and Tolerability Study of ZP-025 Vaginal Gel for the Treatment of Vaginal DrynessCompletedNCT02994342Not applicable
- Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy VolunteersCompletedNCT02495831Phase 1
- Study of the Effects of High-dose N-acetylcysteine (NAC) in Idiopathic Pulmonary Fibrosis (IPF)CompletedNCT00639496Phase 3